Introduction
Cell transplantation holds promises for the delivery of recombinant proteins and the replacement of damaged tissues. Ex vivo cell-based strategies consist of the transplantation of autologous, allogeneic or xenogeneic cells genetically modified for the expression of therapeutic molecules. This approach offers an alternative to the repetitive administrations of bioactive proteins for the treatment of diseases including diabetes, anemia and hemophilia. Yet, the outcome of cell transfer is compromised by the host immune response associated with the expression of antigenic molecules. Histo-incompatibility can originate from either molecular differences inherent to the donor itself or genes newly transferred in the transplanted cells.
We hypothesize that the co-expression by the transplanted cells of immunomodulating molecules together with biotherapeutic factors may allow control of the immune rejection process, while avoiding the side-effects associated with systemic immunosuppression.
Recently, much attention has been focused on molecules able to block costimulatory pathways responsible for the activation of T lymphocytes. During their interac-tocrit. In allogeneic recipients, the same cells induced only a 1-week increase in the hematocrit reflecting an acute rejection process. CTLA4Ig expression significantly extended the survival of mouse Epo-secreting myoblasts in approximately half of syngeneic hosts, whereas it led only to a 1-week improvement effect in allogeneic recipients. When combined with a transient anti-CD154 treatment, CTLA4Ig expression prevented Epo-secreting C 2 C 12 myoblasts from being rejected in allogeneic DBA/2J recipients for at least 1 month. In contrast, the same anti-CD154 treatment alone induced only a 1 week improvement. These results demonstrate that CTLA4Ig co-expression associated with a transient anti-CD154 treatment can prolong the delivery of recombinant proteins via transfer of ex vivo modified cells in allogeneic recipients. Gene Therapy (2001) 8, 58-66.
tion with antigen presenting cells (APC), specific T cell clones need at least two costimulatory signals for the induction of T cell-dependent immunity: the CD154/ CD40 1 and B7/CD28 2 pathways. These two pathways are interrelated. First, the interaction between the T cell receptor (TCR) and the MHC/antigen complex triggers the expression of CD154 on T cells. CD154 binds the CD40 receptor, which in turn up-regulates the expression of B7.1 and B7.2 on the surface of the APC. 3 Second, B7 triggers the CD28 receptor on the surface of the resting T cell, which becomes activated. Engagement of the TCR in the absence of a second signal induces the apoptosis of T cells or leads them to an anergic state characteristic of antigen-specific non-responsiveness. Therefore, each of these two pathways constitutes a key mechanism regulating T cell-dependent immunity.
The fusion protein CTLA4Ig is a soluble derivative of the receptor CTLA4 (CD152) having a 10 to 20 × higher affinity for B7 than CD28. CTLA4Ig thus competitively blocks costimulation through the CD28 receptor, while anti-CD154 monoclonal antibodies block the activation of the CD40 pathway.
Immunomodulation based on systemic administration of CTLA4Ig and/or anti-CD154 antibodies has been successfully applied in organ transplantation. Various studies demonstrated the synergistic effect of blocking both the B7/CD28 and CD154/CD40 costimulatory pathways, leading to a dramatically improved outcome for allografted organs. 4, 5 This dual strategy also prolonged the survival of skin and cardiac xenografts. 6 Systemic blockade of T cell costimulation also proved efficient in allotransplantation of pancreatic islets. CTLA4Ig prolonged the survival of pancreatic islets allotransplanted in cynomolgus monkeys.
7 CD154 blockade allowed the long-term survival of mouse islet allografts when combined with injections of donor small lymphocytes 8 and was recently reported to permit the acceptance of allogeneic islets in two non-human primate models. 9, 10 Fewer studies, however, have evaluated the effect of these molecules on transplantation of other cell types. Intraperitoneal injections of CTLA4Ig combined with anti-CD4 monoclonal antibodies improved the efficiency of myoblast allotransplantation. 11, 12 Anti-CD154 treatment prolonged the survival of allogeneic hepatocytes whereas CTLA4Ig did not. 13 The local delivery of CTLA4Ig was recently investigated in various cell transplantation protocols of islet allotransplantation: islets were either coated with CTLA4Ig before implantation 14 or genetically modified by biolistical transfection. 15 Co-transplantation of syngeneic C 2 C 12 myoblasts expressing CTLA4Ig together with allogeneic islets prolonged their survival under the mouse kidney capsule. 16 Adenoviral transduction of CTLA4Ig expression was reported to improve the survival of myeloid dendritic cells in allogeneic recipients significantly, 17 as well as pancreatic islets in xenogeneic recipients. 18 Myoblasts originating from the mouse C 2 C 12 cell line are being used as a tool for cell-mediated gene transfer. In vivo, C 2 C 12 myoblasts expressed high and stable levels of transgenes such as Factor IX, 19 human growth hormone, 20 ciliary neurotrophic factor (CNTF) 21 and Epo. [22] [23] [24] Thus, they provide a model for the transplantation of muscle cells, whose capacity to express large amounts of recombinant proteins may find application in cell-based therapies. In the present study, C 2 C 12 myoblasts were genetically engineered to secrete both CTLA4Ig and murine Epo, a reporter gene inducing a rapid production of erythrocytes. We show that CTLA4Ig expression extends the survival of the grafted Eposecreting myoblasts, as reflected by a prolonged increase in the host hematocrit level. This effect can be further improved in allogeneic recipients when combined with a transient treatment with anti-CD154 antibodies, demonstrating the efficacy of this approach in modulating the immune response. Syngeneic C3H mice do not reject native C 2 C 12 myoblasts The immunogenicity of non-transfected C 2 C 12 myoblasts was tested through intramuscular injection of 3 × 10 6 cells in syngeneic C3H mice. In three out of four implanted animals, histological analysis on day 44 revealed the presence of living myoblasts forming an invasive tumor in the host muscle fibers (Figure 1 ). In the remaining mouse, the muscles analyzed by histological examination contained only few infiltrations attributed to the injections of C 2 C 12 myoblasts. Syngeneic C3H and allogeneic DBA/2J, C57BL/6 and BALB/c mice reject mouse Epo-secreting C 2 C 12 myoblasts The hematocrit level of syngeneic C3H mice implanted with 3 × 10 6 msEpo pool #15 C 2 C 12 naked myoblasts increased progressively, reaching 74.2 ± 2.5% on day 14, but then declined to basal levels until day 42, demonstrating the rapid rejection of injected cells (Figure 2 ). Histo- logical analysis also confirmed the regression of the injected cell mass (data not shown).
Results

Transfected
The injection of the same amount of C 2 C 12 myoblasts (H-2 k ) in three allogeneic strains of mice recipients
)) also induced a 1-week initial increase of the hematocrit. During the 3 following weeks, the hematocrit returned to baseline level in all three strains (Figure 2 ), suggesting that C 2 C 12 myoblasts had already been rejected after 1-week residence in allogeneic recipients.
FK506 immunosuppression prolongs the survival of mouse Epo-secreting C 2 C 12 myoblasts in C3H mice One million myoblasts of the non-selected population of mouse Epo-secreting myoblasts were injected into syngeneic C3H mice. A cohort immunosuppressed by daily injections of FK506 was compared to non-immunosuppressed animals. On day 14 after injection, both groups had increased their hematocrit to a similar value ( Figure  3 ). Subsequently, all non-treated mice decreased their hematocrit to the basal level, whereas immunosuppressed C3H mice maintained an elevated value (79.0 ± 2.6% on day 35). Two FK506-treated mice died prematurely during the experiment time course, presumably because of side-effects associated with systemic immunosuppression, repeated anesthesia and elevated hematocrit.
CTLA4Ig expression improves the survival of Eposecreting C 2 C 12 myoblasts in C3H mice Syngeneic C3H recipients were injected intramuscularly with 3 × 10 6 msEpo#15/CTLA4Ig C 2 C 12 myoblasts. All 10 mice initially increased their hematocrit to a mean value of 81.2 ± 0.8% on day 14 ( Figure 4 ). Subsequently, a subgroup of five mice returned to basal level. These mice experienced a variation in their hematocrit not significantly different from those having received non-immunomodulating myoblasts (Table 1) . Remarkably, the remaining mice maintained their hematocrit around 90% over the whole experiment time course, demonstrating the survival of injected cells. The spontaneous death of a mouse on day 40 may be related to its high hematocrit level. Moreover, two mice were prematurely killed since they presented difficulties in moving their injected hind limb. Histological analysis of tibialis anterior and gastrocnemius muscles revealed tumors related to the uncontrolled proliferation of implanted cells.
The same kinetics were observed in mice implanted with the population of C 2 C 12 myoblasts expressing higher amounts of CTLA4Ig (Table 1) . In this case, only two out of 11 animals rejected the injected cells within 2 weeks following implantation.
The serum concentrations of CTLA4Ig and Epo were measured on day 8 and 37 in five mice injected with 3 × 10 6 msEpo#15/CTLA4Ig C 2 C 12 myoblasts. On day 8, CTLA4Ig was detectable in three mice sera, with a maximal value of 8.0 ng/ml (Table 2 ). In the two remaining mice, serum values were below the limit of detection of the ELISA assay. In parallel, serum Epo concentration ranged from 1830 mUI/ml to 3110 mUI/ml ( Table 2) . As suggested by their hematocrits, two recipients rejected the injected cells after 2 weeks. However, graft survival could not be correlated with the serum level of CTLA4Ig at 1 week after implantation.
On day 37, the CTLA4Ig concentration was undetectable in all mice sera (Table 2) , while graft survival was demonstrated in three recipients by elevated hematocrits and detectable levels of Epo, ranging from 20 to 1470 mUI/ml (Table 2) . These discrepancies suggest an immune response against the human Fc portion of CTLA4Ig leading to a decrease in the detection of CTLA4Ig in the sera.
CTLA4Ig expression temporarily delays the acute rejection of Epo-secreting C 2 C 12 myoblasts in allogeneic DBA/2J mice We investigated the survival of C 2 C 12 myoblasts (H-2 k ) expressing both mouse Epo and CTLA4Ig in allogeneic recipients. The hematocrit of DBA/2J mice (H-2 d ) peaked at 70.9 ± 1.0% on day 14 after injection of 3 × 10 6 msEpo#15/CTLA4Ig C 2 C 12 myoblasts and then declined to normal value ( Figure 5 ). Nevertheless, between days 14 and 21, the hematocrit remained at a significantly higher level (P Ͻ 0.0005) as compared with the transplantation of nonimmunomodulating myoblasts. the CD154/CD40 pathway. Implantation of 3 × 10 6 msEpo pool #15 C 2 C 12 myoblasts induced an increase of the mean hematocrit level to 73.0 ± 2.8% on day 14, followed by a decline to the baseline value ( Figure 6 ). This time course suggested that a transient anti-CD154 treat-ment induced a 1-week delay in the rejection process, which was not significantly different from the effect obtained with a sustained expression of CTLA4Ig alone (Table 1) .
CTLA4Ig expression combined with a transient anti-CD154 treatment prevents the acute rejection of Eposecreting C 2 C 12 myoblasts in allogeneic DBA/2J mice As both individual treatments provided only partial protection, we tested whether the combination of CTLA4Ig expression and CD154 blockade could prevent the rejection of allotransplanted C 2 C 12 myoblasts.
Three million msEpo#15/CTLA4Ig C 2 C 12 myoblasts were implanted in DBA/2J recipients treated with anti-CD154 monoclonal antibodies. Their hematocrit level regularly increased to 89.6 ± 1.1% on day 34 ( Figure 7 ) when animals were killed as they all developed tumors in their injected hind limb. A second implanted group was injected with control hamster monoclonal antibodies. In these mice, the mean hematocrit increased to 69.0 ± 1.7% on day 14 and then declined to basal value, demonstrating that control hamster antibodies had no effect on the survival of the grafted cells. Similar results were obtained with the population of C 2 C 12 myoblasts expressing higher amounts of CTLA4Ig ( Table 1 ).
The expression of CTLA4Ig prevents only locally the acute rejection of C 2 C 12 cells in DBA/2J mice transiently treated with anti-CD154 antibodies Four DBA/2J mice simultaneously received 3 × 10 6 msEpo#15/CTLA4Ig C 2 C 12 myoblasts in their left hind limb and 3 × 10 6 msEpo pool #15 C 2 C 12 myoblasts in their right hind limb. These mice were treated with anti-CD154 antibodies as previously described. On the 23rd day after implantation, the animals were killed and the injected muscles analyzed to evaluate the number of surviving C 2 C 12 myoblasts. At the time of death, the serum concentration of CTLA4Ig was very similar in the four mice, with a mean value of 9.3 ± 1.4 ng/ml. All the gastrocnemius muscles injected with CTLA4Ig-expressing cells were characterized by the presence of a large tumor associated with a loss of host muscle fibers ( Figure 8A and C). In contrast, the opposite hind limbs contained only a small tumor mass scattered with mononuclear cell infiltrates and were overall preserved ( Figure 8B and D) . This marked difference suggests that the expression of CTLA4Ig in the left hind limb did not prevent the rejection of C 2 C 12 myoblasts in the opposite limb, an observation indicative of a local protective effect.
Discussion
The present study explores the feasibility of employing a self-immunomodulating cell line as a transplantable source of recombinant proteins. The mouse C 2 C 12 myoblast cell line was genetically engineered to co-express CTLA4Ig and therapeutic amounts of mouse Epo. The expression of CTLA4Ig improves the survival of these myoblasts transplanted in the muscle of syngeneic recipients. In allotransplantation, only the combination of CTLA4Ig expression with a transient systemic anti-CD154 treatment prevents the acute rejection of C 2 C 12 myoblasts.
In a previous study, C 2 C 12 mouse Epo-secreting myoblasts encapsulated in a polymer membrane survived for at least 80 days in both syngeneic and allogeneic mice. 22 In contrast, the same cells injected in the muscle of syngeneic C3H mice only induced a transient increase in host hematocrit demonstrating their rapid elimination. In the present study, this rejection process is further examined by exposing the hosts to a pan-immunosuppressive drug. The stable increase in the hematocrit levels observed with a FK506 treatment reveals that systemic immunosuppression improves the survival of the injected Epo-secreting myoblasts, suggesting an immune mechanism as the cause of their rejection in syngeneic recipients.
On the other hand, native C 2 C 12 myoblasts survive in the muscle of C3H mice and histological analysis 44 days after injection has not revealed any immune response. This suggests that the non-transfected population of C 2 C 12 myoblasts does not inherently express antigens leading to their acute rejection in C3H recipients. Thus, the histoincompatibility of mouse Epo-secreting C 2 C 12 myoblasts must result from the transfer of the mouse Epo expression vector. Antigenicity may be linked to mutations occurring spontaneously or accompanying the integration of plasmid DNA. More likely, it may result from the expression of potentially immunogenic molecules such as the bacterial neomycine phosphotransferase or the mutated dihydrofolate reductase. Some previous reports have described immune responses associated with the introduction of selectable marker genes in immunocompetent hosts. [25] [26] [27] [28] The acute rejection process observed in both syngeneic and allogeneic recipients suggests that C 2 C 12 myoblasts constitute a stringent model of cell transplantation. The expression of class I major histocompatibility complexes (MHC) in response to ␥IFN stimulation accounts for the immunogenicity of the C 2 C 12 cell line (data not shown). In addition, the ability to process antigens 29 associated with the constitutive expression of B7.1 (data not shown) suggest that C 2 C 12 myoblasts may themselves function as antigen presenting cells, as reported for human myoblasts. 30, 31 Like tumor cells, C 2 C 12 myoblasts have an unlimited expansion. They were derived as a clonal subpopulation of primary mouse myoblasts that spontaneously started to proliferate in vitro. 32 Thus, C 2 C 12
Figure 8 Photomicrographs of both hind limbs from a DBA/2J mice 23 days after injection of C 2 C 12 myoblasts. This animal received a transient systemic treatment with anti-CD154 antibodies. (A) A large tumor (T) invading the host gastrocnemius muscle (G) in the left hind limb injected with 3 × 10
myoblasts secreting both mouse Epo and CTLA4Ig. Note the loss of host muscle fibers and the proximity of the popliteal lymph node (LN). (B) The right hind limb injected with 3 × 10 myoblasts secreting only mouse Epo. The remaining tumor (T) appears much smaller with preserved gastrocnemius muscle fibers (G). (C) Higher magnification of (A) showing the non-organized cell mass in the host muscle. (D) Higher magnification of (B) showing infiltrates of mononuclear cells scattered in the tumor. Scale bars: (A, B) 1 mm; (C, D) 100 m.
have not developed intrinsic properties to escape the host immune system, in contrast to most of the tumor cells derived in immunocompetent animals.
The expression of CTLA4Ig prolonged the survival of the grafted cells in only 50% of syngeneic C3H recipients. A bimodal response has similarly been observed in other studies based on a local administration of CTLA4Ig. 14, 15, 33, 34 The explanation for this response remains unclear. The expression level of CTLA4Ig may have to reach a threshold value in order to diffuse up to the regional lymph nodes and exert its immunomodulating effect. The fact that a two-fold increase in CTLA4Ig expression level improved the proportion of animals accepting the grafted cells supports this hypothesis. However, the concentration of CTLA4Ig in the serum of C3H recipients at 1 week after implantation was not predictive of graft outcome. On day 37, CTLA4Ig could not be detected in all mice sera, even though three mice maintained elevated hematocrit levels. We hypothesize that these results are related to the human origin of the CTLA4Ig Fc portion, leading to an immune response in mice recipients. 34 On the other hand, this bimodal response may reflect a dual effect of the CTLA4Ig molecule, which competes for B7 with two receptors having antagonistic effects: the CD28 receptor, activating the T cell, and the CTLA4 receptor, a negative regulator of T cell function. By competition with the latter, CTLA4Ig may lead to a stimuGene Therapy lation of T cell responses: in the absence of CD28, B7 blockade accelerates allograft rejection 35 by inhibition of the CTLA4 signaling pathway. In addition, the CTLA4 pathway is necessary for the induction of long-term allograft survival. 36, 37 As CTLA4 has a 10 to 20 times higher affinity than CD28 for the B7 ligand, the CTLA4Ig molecule is believed to block predominantly the CD28 pathway.
In allogeneic recipients, the combination of CTLA4Ig expression with a transient CD154 blockade prevented C 2 C 12 myoblasts from being acutely rejected. This demonstrates the adequacy of a sustained CTLA4Ig delivery to prolong the immunomodulation induced by a systemic, transient administration of anti-CD154 antibodies.
CTLA4Ig is intended to block costimulation when naive lymphocytes recognize graft antigens. Therefore, the manner of antigen presentation is a key issue to determine the most appropriate mode of CTLA4Ig delivery. Since indirect presentation has proved effective in various transplantation models including allotransplantation, much attention focuses on host antigen presenting cells, the most efficient being dendritic cells. Presumably, dendritic cells capture graft antigens, process them and migrate to the regional lymph nodes where they encounter a large population of naive lymphocytes. Thus, CTLA4Ig should reach the draining lymphoid organs to interfere with T cell costimulation. Its local delivery may appear particularly adequate in sites, such as the brain, whose anatomical structure limits lymphatic drainage. In the present study, the cells were injected in the hind limb muscles, close to the draining popliteal lymph node. This may account for the local immunomodulation observed with this mode of CTLA4Ig delivery.
The long-term acceptance of rat heart allografts induced by intracardial injection of an adenovirus expressing CTLA4Ig has been reported to be associated with systemic immunosuppressive effects. 38 The CTLA4Ig level in the serum ranged between 10 and 100 g/ml. In the present study, an immunomodulating effect has been obtained even though the measured serum concentration of CTLA4Ig did not exceed 20 ng/ml. This level of expression may appear compatible with a local blockade of T cell costimulation affecting only the regional lymph node. This hypothesis is supported by the marked difference observed in the survival of CTLA4-Ig-expressing as compared with non-expressing myoblasts injected in the opposite hind limb. Delivering the immunomodulating agent in the graft environment provides a regional specificity without exposing the host to side-effects related to general immunosuppression such as increased infection risk. Additionally, while T cell costimulation has proved critical under certain conditions, 39 some viruses and other pathogens trigger protective immune responses in absence of costimulatory signals including the B7/CD28 and CD40/CD154 pathways. 40, 41 A maintenance therapy with agents blocking T cell costimulation was required for the long-term survival of islets and kidneys allografted in non-human primate models. 5, 9, 10 The constant expression of CTLA4Ig may provide a means to prevent the late rejection events without the constraints of systemic treatments. However, the long-term efficacy of a sustained localized delivery remains to be tested with non-dividing cells.
In the present study, CTLA4Ig expression prolongs the increase of host hematocrit in response to the secretion of Epo, a reporter molecule inducing an overproduction of erythrocytes. This physiologic effect reflects the viability of the grafted cells, since C 2 C 12 myoblasts maintain a stable Epo expression level even after prolonged residence in mouse recipients. 22 This correlation was confirmed by the histological examination of the injected muscles.
Genetically engineered cells constitute a reliable source of recombinant proteins. Yet, the elimination of grafted cells associated with the host immune response appears as the main obstacle in the elaboration of an efficient delivery system based on cell transfer. The use of cells with self-immunomodulating properties provides an opportunity to overcome some of these immune barriers while avoiding systemic host immunosuppression. This approach, associated with the emergence of reliable cell sources for the constant or even regulated delivery of proteins, offers new perspectives in the cell therapy approaches of numerous diseases including anemia, ␤-thalassemia and diabetes.
Materials and methods
Construction of expression plasmids
The sequence coding for the fusion protein CTLA4Ig was a gift of Dr P Lane (Division of Immunity and Infection, Medical School, Birmingham, UK) and was contained in a previously described plasmid. 42 It is a chimera of the cDNA coding for mouse CTLA4 and a part of the genomic human IgG1 gene comprising the hinge and the CH2 and CH3 regions. The whole fragment was excised by a digestion with the enzymes SacI and BamHI and subcloned between the XhoI and BamHI sites of the pMTZeo vector, resulting in the pMT-CTLA4Ig-Zeo plasmid.
The expression cassette of the pMT-Zeo expression vector is derived from the pNUT-RD vector:
21 a fragment containing the intron 2 of rat insulin was inserted in the BamHI site between the metallothionein promoter and the human growth hormone 3Ј untranslated region. The complete expression cassette was excised by a digestion with the enzymes EclXI and BglII and blunt ended. This fragment was finally inserted in the pSV-Zeo vector (Invitrogen, San Diego, CA, USA) digested with BamHI and blunt ended. This BamHI digestion removed the SV40 promoter, multiple cloning site and SV40 polyA of the pSV-Zeo expression vector.
Murine Epo was encoded by the previously described pPI-mouse Epo-ND vector, 22 whose expression cassette is driven by the mouse phosphoglycerate kinase 1 (PGK-1) promoter. This plasmid contains the bacterial neomycin phosphotransferase and the mutated dihydrofolate reductase genes, two selectable marker genes.
Cell culture and transfection
Mouse C 2 C 12 myoblasts derived from leg skeletal muscles of an adult C3H (H-2 k ) mouse 32 were obtained from American Type Culture Collection (CRL 1772; ATCC, Rockville, MD, USA). C 2 C 12 cells were grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal calf serum, 2 mm l-glutamine, 4.5 g/l glucose, 100 U/ml penicillin and 100 U/ml streptomycin. Cells were transfected by calcium phosphate precipitation (mammalian transfection kit, Stratagene, La Jolla, CA, USA) with the plasmid pPI-mouse Epo-ND. After 2 weeks of selection with 0.8 mg/ml G418, cells were incubated with increasing concentrations of methotrexate (1 to 200 m) over a 6-week period to amplify the copy number of the integrated plasmids. Selected pools were obtained by diluting the total population at a final concentration of 10 cells per well in 96-well plates (Costar, Cambridge, MA, USA). Pool #15 of mouse Epo secreting C 2 C 12 myoblasts was then retransfected with the plasmid pMT-CTLA4Ig-Zeo and incubated for 3 weeks with both 0.8 mg/ml G418 and 250 g/ml Zeocin (Invitrogen). Finally native mouse C 2 C 12 myoblasts were cotransfected Cambridge, MA, USA). Pool #15 of mouse Epo secreting Zeo plasmids. At the end of the initial 3-week selection with both Zeocin and G418, the copy number of both plasmids was amplified in response to increasing concentrations of methotrexate.
Determination of Epo and CTLA4Ig expression levels C 2 C 12 cells were plated in growth medium at a density of 1 × 10 5 cells per well in six-well culture dishes (Costar). Conditioned media were obtained by incubating C 2 C 12 myoblasts in 1 ml of fresh medium for 1 h.
Epo concentration was determined using an enzyme linked immunosorbent assay (ELISA) system (Quantikine IVD, R&D Systems, Minneapolis, MN, USA). Cross-reaction of the kit allowed detection of mouse Epo in sera and culture supernatants and the corrected absolute values of mouse Epo secretion were determined employing mouse Epo standards (Roche Diagnostics, Rotkreuz, Switzerland). The correlation function was 4.2x, where x is the ELISA measured value of the mouse Epo sample.
CTLA4Ig concentration was evaluated using an ELISA assay. 33 Flat-bottomed 96-well plates (Nunc, Roskilde, Denmark) were coated for 30 min at 37°C with 100 l per well of a 1/2000 diluted AffiniPure mouse antihuman IgG Fc␥ fragment-specific antibody (Jackson ImmunoResearch Laboratories, West Grove, PA, USA). After blocking, 100 l triplicates of samples and standards (ChromPure human IgG Fc fragment, Jackson) were incubated for 2 h at 37°C. A 1/5000 dilution of alkaline phosphatase-conjugated goat anti-human IgG Fc fragment-specific antibody (Jackson) was then added and incubated for 1 h at 37°C. After detection using a 1 mg/ml solution of pNPP (Fluka, Buchs, Switzerland), the reaction was stopped with 100 l of 3 N NaOH per well. Plates were read at a wavelength of 405 nm and a reference wavelength of 550 nm.
Binding activity of CTLA4Ig expressed by C 2 C 12 myoblasts A clone of rat glioblastoma C6 cells transfected for murine B7.1 expression was used to test the binding activity of CTLA4Ig. B7.1 positive C6 cells were incubated for 1 h at 4°C with supernatants of CTLA4Ig expressing C 2 C 12 myoblasts. Cells were then washed with Hanks' balanced salt solution (HBSS) and incubated for 30 min at 4°C with FITC conjugated goat anti-human IgG1 Fab fragments (BioSource International, Camarillo, CA, USA). Fluorescence on a total of 5000 cells was finally analyzed on a EPICS-Profile II flow cytometer (Coulter, Hialeah, FL, USA).
Injection of anti-CD154 and control antibodies MR1, a hamster antibody specific to murine CD154, 43 was kindly provided by Biogen (Cambridge, MA, USA). 250 g of MR1 were injected in the peritoneal cavity of DBA/2J mice on day −1, 0 and +3 following transplantation. Control DBA/2J recipients received control hamster antibodies according to the same protocol.
Intramuscular injection of C 2 C 12 mouse myoblasts C 2 C 12 mouse myoblasts were harvested from confluent cultures by trypsinization, washed three times with HBSS and finally resuspended at a concentration of 10 5 cells per l HBSS. Six to 8-week-old mice obtained from Iffa Credo (Saint-Germain sur l'Abresle, France) were anesthetized with isofluran and the skin of the hind limb opened for surgery. Using a Hamilton syringe with a 26S-gauge needle, 3 million cells were injected in the tibialis anterior and gastrocnemius muscles of each mice. The skin was then closed using a 6.0 Vicryl (Ethicon, Norderstedt, Germany) suture. Upon recovery, the mice were returned to the animal care facility where they had access to food and water ad libitum.
Blood collection and hematocrit measurement
Under isofluran general anesthesia, blood was drawn weekly from the mice tail vein into heparinized capillary tubes. The hematocrit was then measured by a standard microhematocrit method. 44 For determination of CTLA4Ig and Epo in the serum, 500 l of blood were obtained via retro-orbital bleeds on Gene Therapy anesthetized mice and cardiac punctures were performed at the time of death. Serum was stored at −20°C until assayed.
Immunosuppression
Mice were pretreated for 2 days with FK506 (2.5 mg/kg) (Prograf; Fujisawa, Mü nchen, Germany). After injection of the myoblasts, these animals were treated daily for 35 days with 2.5 mg/kg of FK506. The animals were briefly anesthetized with isofluran and the drug was injected using an insulin syringe (Omnican 30; Braun Petzold, Melsungen, Germany) in the quadriceps muscle of both hind limbs, alternately.
Histology of injected muscles
Mice were killed with an overdose of pentobarbital and perfused transcardially with 4% paraformaldehyde. The injected hind limbs were placed in 4% paraformaldehyde for 48 h and then in 25% sucrose for 48 h. The tibialis anterior and gastrocnemius muscles were dissected and frozen on crushed dry ice. Longitudinal 14-m thick sections were cut on a sliding microtome cryostat (Cryocut 1800, Leica, Nussloch, Germany) and finally stained with hematoxylin and eosin.
Statistical analysis
Data are expressed as mean ± s.e.m. The data obtained were analyzed for statistical significance between control and experimental groups using a variance analysis (ANOVA) followed by a Fischer PLSD post-hoc test. A P value of less than 0.05 was considered to be statistically significant.
